/
IPSC
$2.41+$0.09 (+3.88%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$418.4M
180M shares
52-week range
$0.44 – $3.04
76% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
1.61%
Moderate
Price (6 mo)
Loading chart…
Change$-26.65
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $5.2M | $2.2M | $6.6M | $109.2M |
| Cost of revenue | $249.0K | $1.8M | $4.6M | $0 | $0 | $0 | $13.1M |
| Gross profit | −$249.0K | −$1.8M | −$4.6M | $5.2M | $2.2M | $6.6M | $96.1M |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% | 88.0% |
| R&D | $14.3M | $39.7M | $75.6M | $97.2M | $92.7M | $107.2M | $95.7M |
| Operating income | −$20.0M | −$49.2M | −$94.9M | −$133.8M | −$146.5M | −$138.1M | −$15.0M |
| EBITDA | −$244.5M | −$51.4M | −$89.9M | −$121.2M | −$121.2M | −$111.5M | $3.5M |
| Net income | −$244.8M | −$53.6M | −$95.8M | −$130.9M | −$136.7M | −$126.6M | −$9.6M |
| Net margin | — | — | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
| EPS (diluted) | -4.49 | -1.00 | -1.74 | -2.27 | -2.30 | -1.61 | -0.11 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $5M | $-0.45 | $-0.50–$-0.39 | 3 |
| 2027 | $4M | $-0.44 | $-0.56–$-0.28 | 3 |
| 2028 | $1M | $-0.35 | $-0.39–$-0.31 | 2 |
| 2029 | $375000 | $-0.36 | $-0.36–$-0.36 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.88
Price
$2.41
Implied upside
+19%
Peer comparison
Century Therapeutics, Inc. Common Stock
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
www.centurytx.com- Employees
- 78
- IPO / List date
- Jun 18, 2021
- HQ
- PHILADELPHIA, PA
Held by traders on TradeandTell
No one on the platform currently holds IPSC.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 906,827 | $2.0M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IPSC yet.
